Relation between Apelin，IRS-2 protein and prognosis of gastric cancer patients

doi:10.3969/j.issn.1673-8640.2024.05.004

Abstract

Abstract:

Objective To investigate the relation between the expressions of adipocyte cytokine Apelin and insulin receptor substrate 2（IRS-2） and the prognosis of gastric cancer patients. Methods A total of 87 patients with gastric cancer diagnosed for the first time in Hengshui Hospital of Traditional Chinese Medicine from January 2014 to December 2015 were enrolled. Postoperative cancer tissue samples and adjacent tissue samples（mucosal tissue 3 cm away from tumor margin） of all the patients were collected，and clinical data were collected as well. The expressions of Apelin and IRS-2 in cancer tissues and adjacent tissues of patients with gastric cancer were determined. The correlation between Apelin and IRS-2 was analyzed by column correlation number. Kaplan-Meier survival curve was used to evaluate the survival of patients with gastric cancer，and Cox proportional risk regression analysis was used to evaluate the risk factors for the death of gastric cancer patients. Results The positive expression rates of Apelin were 73.56%（64/87） and 5.75%（5/87） in cancer tissues and adjacent tissues，and the positive expression rates of IRS-2 were 56.32%（49/87） and 6.90%（6/87），respectively. There was statistical significance in the positive expression rates of Apelin and IRS-2 among gastric cancer patients with different tumor differentiation degrees，TNM stages and lymphatic metastasis（P<0.05），while there was no statistical significance in the positive expression rates of Apelin and IRS-2 among gastric cancer patients with different sex，ages and tumor sizes（P>0.05）. Apelin and IRS-2 expressions were weakly correlated in cancer tissues（column correlation number was 0.329，P=0.024）. According to the expressions of Apelin and IRS-2，gastric cancer patients were classified into positive group and negative group. The overall survival times of Apelin positive group and IRS-2 positive group were lower than those of Apelin negative group and IRS-2 negative group，respectively（P<0.05）. Positive Apelin，positive IRS-2，low tumor differentiation，lymphatic metastasis and TNM stage Ⅲ were all risk factors for death in gastric cancer patients [hazard ratios（HR） were 3.015，2.678，2.898，2.745 and 3.266，95% confidence intervals（CI）were 1.077-8.438，1.326-5.408，1.120-7.501，1.081-6.972 and 1.259-8.474，respectively]. Conclusions The high expressions of Apelin and IRS-2 may increase the risk of poor prognosis of gastric cancer patients，and they may be used as prognostic indicators of gastric cancer patients.

Key words: Apelin, Insulin receptor substrate-2, Gastric cancer, Pathological characteristic, Prognosis

CLC Number:

R446.1

LIU Xuewei, LI Kunpeng, SONG Junyu, ZHAO An. Relation between Apelin，IRS-2 protein and prognosis of gastric cancer patients[J]. Laboratory Medicine, 2024, 39(5): 438-442.

Figures/Tables 4

References 20

[1]	梁春芳, 朱康宁, 张琦. 血清miR-21、miR-135a对胃癌患者化疗后复发和转移的预测价值[J]. 检验医学, 2022, 37(5):417-422. DOI
[2]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[3]	TIAN J, LIU G, ZUO C, et al. Genetic polymorphisms and gastric cancer risk:a comprehensive review synopsis from meta-analysis and genome-wide association studies[J]. Cancer Biol Med, 2019, 16(2):361-389.
[4]	姜志超. 晚期胃癌一线免疫治疗的现状与进展[J]. 中国肿瘤临床, 2023, 50(4):206-211.
[5]	FENG M, YAO G, YU H, et al. Tumor apelin,not serum apelin,is associated with the clinical features and prognosis of gastric cancer[J]. BMC Cancer, 2016, 16(1):794.
[6]	GORGISEN G, KARATAS U, ATES C, et al. Association of IRS1 Gly972Arg and IRS2 Gly1057Asp polymorphisms with gastric cancer in Turkish subjects[J]. Oncol Lett, 2020, 20(2):2016-2020. DOI PMID
[7]	陈慧娟, 王景, 王爱琴. 基于高通量靶向测序的常见实体肿瘤基因突变图谱研究[J]. 检验医学, 2020, 35(7):710-715. DOI
[8]	SHAH D, BENTREM D. Environmental and genetic risk factors for gastric cancer[J]. J Surg Oncol, 2022, 125(7):1096-1103. DOI PMID
[9]	BAI N, PENG E, QIU X, et al. CircFBLIM1 act as a ceRNA to promote hepatocellular cancer progression by sponging miR-346[J]. J Exp Clin Cancer Res, 2018, 37(1):172. DOI PMID
[10]	GRINSTEAD C, YOON S. Apelin,a circulating biomarker in cancer evaluation:a systematic review[J]. Cancers(Basel), 2022, 14(19):4656.
[11]	HUANG Z, LUO X, LIU M, et al. Function and regulation of apelin/APJ system in digestive physiology and pathology[J]. J Cell Physiol, 2019, 234(6):7796-7810. DOI PMID
[12]	WYSOCKA M B, PIETRASZEK-GREMPLEWICZ K, NOWAK D. The role of apelin in cardiovascular diseases,obesity and cancer[J]. Front Physiol, 2018, 9:557.
[13]	ANTUSHEVICH H, WÓJCIK M. Review:apelin in disease[J]. Clin Chim Acta, 2018, 483:241-248.
[14]	LI H, KENTISH S J, WITTERT G A, et al. Apelin modulates murine gastric vagal afferent mechano sensitivity[J]. Physiol Behav, 2018, 194:466-473.
[15]	GAO J, FENG X, WANG F, et al. MicroRNA-448 inhibits the progression of non-small-cell lung cancer through regulating IRS2[J]. J Cell Biochem, 2019, 120(8):13453-13463. DOI PMID
[16]	曹建, 万相斌, 孙淼淼, 等. 结直肠癌组织IRS-2蛋白表达临床意义[J]. 中华肿瘤防治杂志, 2018, 25(20):1440-1445.
[17]	邹华伟, 王玉强. IRS-1与IRS-2在乳腺癌组织中的表达及与其临床病理特征和预后的关系[J]. 实用癌症杂志, 2020, 35(1):53-56.
[18]	ZHAO X M, CHEN J, YANG L, et al. Association between IRS-2 G1057D polymorphism and risk of gastric cancer[J]. World J Gastrointest Oncol, 2012, 4(1):9-15.
[19]	江振洲, 袁子航, 孙丽新, 等. 中国药物作用靶点研究进展(Ⅰ)[J]. 药学进展, 2020, 44(6):433-450.
[20]	孙军萍, 黎宗保, 韩耀光, 等. 妊娠糖尿病患者血清Omentin-1、IRS-1、IRS-2与胰岛素抵抗的关系[J]. 中国妇产科临床杂志, 2020, 21(1):83-84.

临床病理特征	例数	Apelin阳性/ [例（%）]	IRS-2阳性/ [例（%）]	临床病理特征	例数	Apelin阳性/ [例（%）]	IRS-2阳性/ [例（%）]
性别				肿瘤分化程度
男	59	42（71.19）	33（55.93）	中高分化	48	30（62.50）	22（45.83）
女	28	22（78.57）	16（57.14）	低分化	39	34（87.18）	27（69.23）
χ²值		0.533	0.011	χ²值		8.106	4.788
P值		0.466	0.915	P值		0.004	0.029
年龄				淋巴转移
<60岁	39	28（71.79）	21（53.85）	有	65	55（84.62）	44（67.69）
≥60岁	48	36（75.00）	28（58.33）	无	22	9（40.91）	5（22.73）
χ²值		0.114	0.176	χ²值		16.145	13.509
P值		0.736	0.675	P值		<0.001	<0.001
肿瘤大小				TNM分期
<5 cm	37	27（72.97）	19（51.35）	Ⅰ~Ⅱ期	38	23（60.53）	9（23.68）
≥5 cm	50	37（74.00）	30（60.00）	Ⅲ期	49	41（83.67）	40（81.63）
χ²值		0.148	0.647	χ²值		5.896	4.773
P值		0.700	0.421	P值		0.015	0.029

临床病理特征	例数	Apelin阳性/ [例（%）]	IRS-2阳性/ [例（%）]	临床病理特征	例数	Apelin阳性/ [例（%）]	IRS-2阳性/ [例（%）]
性别				肿瘤分化程度
男	59	42（71.19）	33（55.93）	中高分化	48	30（62.50）	22（45.83）
女	28	22（78.57）	16（57.14）	低分化	39	34（87.18）	27（69.23）
χ²值		0.533	0.011	χ²值		8.106	4.788
P值		0.466	0.915	P值		0.004	0.029
年龄				淋巴转移
<60岁	39	28（71.79）	21（53.85）	有	65	55（84.62）	44（67.69）
≥60岁	48	36（75.00）	28（58.33）	无	22	9（40.91）	5（22.73）
χ²值		0.114	0.176	χ²值		16.145	13.509
P值		0.736	0.675	P值		<0.001	<0.001
肿瘤大小				TNM分期
<5 cm	37	27（72.97）	19（51.35）	Ⅰ~Ⅱ期	38	23（60.53）	9（23.68）
≥5 cm	50	37（74.00）	30（60.00）	Ⅲ期	49	41（83.67）	40（81.63）
χ²值		0.148	0.647	χ²值		5.896	4.773
P值		0.700	0.421	P值		0.015	0.029

项目	β值	标准误	Wald值	P值	HR值（95%CI）
Apelin（阳性与阴性）	1.10	0.53	4.417	0.036	3.015（1.077~8.438）
IRS-2（阳性与阴性）	0.99	0.36	7.547	0.006	2.678（1.326~5.408）
肿瘤分化程度（低分化与中高分化）	1.06	0.49	4.809	0.028	2.898（1.120~7.501）
淋巴转移（有与无）	1.01	0.48	4.508	0.034	2.745（1.081~6.972）
TNM分期（Ⅲ期与Ⅰ~Ⅱ期）	1.18	0.49	5.920	0.015	3.266（1.259~8.474）

项目	β值	标准误	Wald值	P值	HR值（95%CI）
Apelin（阳性与阴性）	1.10	0.53	4.417	0.036	3.015（1.077~8.438）
IRS-2（阳性与阴性）	0.99	0.36	7.547	0.006	2.678（1.326~5.408）
肿瘤分化程度（低分化与中高分化）	1.06	0.49	4.809	0.028	2.898（1.120~7.501）
淋巴转移（有与无）	1.01	0.48	4.508	0.034	2.745（1.081~6.972）
TNM分期（Ⅲ期与Ⅰ~Ⅱ期）	1.18	0.49	5.920	0.015	3.266（1.259~8.474）